Caricamento...
Chimeric Antigen Receptor T-Cell Therapy for Lymphomas
It is estimated that 2.1% of the population of the United States will develop non-Hodgkin lymphoma (NHL) in a lifetime. With treatment, 71% of patients with NHL live to 5 years. Because current drugs used for treatment do not cure all patients and cause serious adverse effects, new strategies have b...
Salvato in:
| Pubblicato in: | Hosp Pharm |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5735711/ https://ncbi.nlm.nih.gov/pubmed/29276275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0018578717726517 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|